| 标题： | 妇科恶性肿瘤免疫治疗中国专家共识(2023年版) |
| title： | Chinese Expert Consensus on Immunotherapy for Gynecological Malignant Tumors (2023 Edition) |
| 版本： | 原创版 |
| version： | Original |
| 分类： | 专家共识 |
| classification： | Experts consensus |
| 领域： | 诊疗 |
| field： | Diagnosis and Treatment |
| 国家和地区： | 中国 |
| Country and region： | China |
| 指南使用者： | 临床从事妇科肿瘤工作的医务人员 |
| Guide users： | Medical staff engaged in gynecological oncology work in clinical practice |
| 证据分级方法： | 本共识采用以下推荐级别(表1)，无特殊说明者推荐级别均为2A类。 表1推荐级别及其代表意义 推荐级别 代表意义 1类 基于高级别临床研究证据，专家意见高度一致 2A类 基于低级别临床研究证据，专家意见高度一致；或基于高级别临床研究证据，专家意见基本一致 2B类 基于低级别临床研究证据，专家意见基本一致 3类 不论基于何种级别临床研究证据，专家意见明显分歧 |
| Evidence grading method： | This consensus adopts the following recommendation levels (Table 1), and for those without special instructions, the recommendation levels are all Class 2A. Table 1 Recommendation Levels and Their Representative Significance Recommendation level represents significance Class 1 is based on advanced clinical research evidence, with highly consistent expert opinions Class 2A is based on low-level clinical research evidence, with highly consistent expert opinions; Or based on advanced clinical research evidence, expert opinions are generally consistent Category 2B is based on low-level clinical research evidence, and expert opinions are generally consistent No matter what level of clinical research evidence is based on, there are obvious differences in expert opinions among the three categories |
| 制定单位： | 中国抗癌协会肿瘤内分泌专业委员会 |
| Formulating unit： | Onco-Endocrinology Special Committee of China Anti Cancer Association |
| 注册时间： | 2023-05-31 |
| Registration time： | |
| 注册编号： | PREPARE-2023CN373 |
| Registration number： | |
| 指南制订的目的： | 中国抗癌协会肿瘤内分泌专家委员会牵头，组织肿瘤领域的专家，依据高级别临循证学依据，通过专家共同讨论及投票，形成《妇科恶性肿瘤免疫治疗中国专家共识(2023年版)》，供国内同行参考，以期进一步规范妇科恶性肿瘤免疫治疗的临床实践。 |
| Purpose of the guideline： | The Onco-Endocrinology Special Committee of China Anti Cancer Association led the organization of experts in the field of cancer. Based on high-level evidence-based clinical evidence, experts jointly discussed and voted to form the "Chinese Expert Consensus on Immunotherapy for Gynecological Malignant Tumors (2023 Edition)" for reference by domestic peers, in order to further standardize the clinical practice of immunotherapy for gynecological malignant tumors. |
